Nick Talken

And even that to me was too broad.

Like we are just doing chemistry and materials.

So biotech, pharma, you know, then we might dabble a little bit in those types of areas.

Right.

If there's like a butt up next to them.

But for the most part, those are different.

Like a protein sequence is much different than a small molecule, which is much different than a DNA sequence.

And so if you try to build some generic AI across all of it, you end up spreading the peanut butter, so to speak.

And you don't get the value that the data actually can provide.

I hope so, man.

I hope so.

Me too.

Yeah.

So I'll try to maybe I'll try to address both those.

So I hope that the industry, the industry has not had a lot of urgency for many, many years, this industry that we serve.

And now that's changing.

We're starting to see urgency because of margin erosion, because of competitive pressures in other regions in the world.

And because there's other companies now that are popping up that are doing fully autonomous laboratory work with high throughput lab testing that are competing with the more traditional chemical industry.

And so I think as part of this solve to that, you know, companies like Albert,

are playing a role to help these companies jump into the future a little bit, or jump maybe into the present from the past.